Will doubled Wegovy supply ease US patient access to obesity drugs?

Question

Accepted Answer

Increased Supply of Lower-Dose Wegovy to Offer Some Access for New US Patients

Novo Nordisk is set to more than double the supply of lower doses of its obesity drug Wegovy in the United States, a move intended to allow some new patients to commence treatment. This increase in weekly injection volumes is expected to be reflected in US prescription data in the coming weeks, offering a partial solution to the significant demand challenges the drug has faced. While this development is positive for a segment of prospective patients, it is important to note that four out of five available dose strengths of Wegovy are still experiencing shortages.
Increased Lower-Dose Availability

The Danish pharmaceutical company will significantly increase the output of the lower-strength versions of Wegovy. This action is a direct response to the persistent inability of Novo Nordisk to meet the overwhelming demand for the drug, which had previously led to supply reductions for the lowest three doses in May. The CEO indicated that this boost in weekly injection volumes is specifically aimed at enabling some new patients to initiate therapy.
Ongoing Shortages for Multiple Strengths

Despite the planned increase in lower-dose supply, the broader availability of Wegovy in the US remains constrained. Data from the US Food and Drug Administration website indicates that four out of the five available dose strengths are currently in shortage. This situation highlights that while some new patients may gain access, the overall supply of Wegovy, particularly for higher doses that may be prescribed as treatment progresses, continues to be a challenge.
Decline in New Prescriptions

The impact of the supply limitations on patient access is evident in prescription data. For the week ending January 19, approximately 54,150 new US prescriptions were written for Wegovy. This figure represents a substantial decrease from the peak of 135,000 new prescriptions recorded in May, according to healthcare data firm IQVIA. The current increase in lower-dose supply aims to begin reversing this downward trend for new patient initiations.

Reading history

Hide →

This history is cleared when the page is closed.

Will doubled Wegovy supply ease US patient access to obesity drugs?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends